TOPIRAMATE (TOPAMAX): START OF SAFETY REVIEW TRIGGERED BY A STUDY REPORTING AN INCREASED RISK OF NEURODEVELOPMENTAL DISABILITIES IN CHILDREN WITH PRENATAL EXPOSURE

A new safety review into topiramate has been initiated by the Medicines and Healthcare products Regulatory Agency (MHRA) as a result of an observational study reporting an increased risk of neurodevelopmental disabilities in children whose mothers took topiramate during pregnancy. Topiramate is known to be associated with an increased risk of congenital malformations and effects on fetal growth if used during pregnancy. Healthcare professionals should continue to counsel patients who can become pregnant on the known and emerging risks of topiramate for an unborn baby and on the need to use effective contraception throughout use.

Advice for healthcare professionals:

- A new safety review has started to assess the benefits and risks of topiramate and to consider whether further measures are required to reduce the risk of harm associated with topiramate use during pregnancy
- The new safety review was triggered by a large observational study reporting that prenatal exposure to topiramate is associated with an increased risk of autism spectrum disorders, intellectual disability, and neurodevelopmental disorders
- Of the antiepileptic medicines reviewed for use in pregnancy, lamotrigine and levetiracetam continue to be considered the safer for the baby since they were not associated with an increased risk of birth defects – see advice following comprehensive safety review of antiepileptic drugs in pregnancy
It remains vital that the strict restrictions for valproate prescribing in women and girls of childbearing potential are followed given the known significant risks if valproate is used in pregnancy (see below)

Reminder of current advice for topiramate:

- Do not prescribe topiramate during pregnancy for migraine prophylaxis
- Ensure any patients of childbearing potential know to use highly effective contraception throughout treatment with topiramate
- Counsel patients on the importance of avoiding pregnancy during topiramate use due to these emerging data and also the established increased risks of major congenital malformations and fetal growth restriction in babies exposed to topiramate in-utero
- Topiramate may reduce the effectiveness of steroidal contraceptives, including oral contraceptives, therefore consider alternative or concomitant methods (see below)
- For migraine prophylaxis, topiramate can be withdrawn in pregnancy by an appropriate prescriber but alternative treatments should be considered
- For epilepsy, urgently refer anyone on topiramate who is planning a pregnancy or who is pregnant for specialist advice on their antiepileptic treatment

Advice to provide to patients:

- Do not stop taking topiramate without first discussing it with your doctor
- Topiramate can harm the way an unborn baby grows and develops during pregnancy – see MHRA patient leaflet on epilepsy medicines and pregnancy
- A new study has also linked topiramate to an increased risk of autism spectrum disorders and intellectual disabilities (effects on learning and development) in children exposed to it during pregnancy
- The MHRA and its independent experts are investigating whether there needs to be changes to how topiramate can be used in UK patients – we will communicate the outcomes of this review once it has concluded
- If you are taking topiramate for epilepsy and are planning a pregnancy, urgently talk to your doctor for a specialist review – there are other epilepsy medicines that are not associated with an increased risk of birth defects in pregnancy
- If you are taking topiramate for migraine and planning a pregnancy, talk to your prescriber about alternative treatments that can be used in pregnancy as soon as possible
- Anyone who is able to get pregnant should have a pregnancy test before they start topiramate treatment and use effective contraception while taking topiramate
- Topiramate can reduce the effectiveness of hormonal contraception in preventing unplanned pregnancy – talk to a healthcare professional about the best contraception for you while you are taking topiramate

Further information on topiramate and known harms if used in pregnancy

Topiramate is used:
- To prevent migraine headaches in adults after consideration of possible alternative treatment options
- Alone to treat seizures in adults and children aged older than 6 years
• With other medicines to treat seizures in adults and children aged 2 years and older

It is available as tablets, a liquid oral solution, or as capsules that can be swallowed whole or sprinkled on soft food. The brand name of topiramate is Topamax, and so this may also appear on the box.

Following a comprehensive national review by the Commission on Human Medicines into the safety of antiepileptic drugs in pregnancy, including topiramate, in January 2021 new safety advice was published with updated patient advice, and a Public Assessment Report.

The review showed topiramate exposure in-utero to be associated with an increased risk of congenital malformations (approximately 4 or 5 cases per 100 babies, compared with 2 or 3 in the general population). Topiramate was also shown to be associated with an increased risk of the baby being born of low birth weight and small for gestational age (fetal growth restriction).

At the time of the 2021 review, some data had raised concerns that topiramate use during pregnancy may be associated with an increased risk of autism spectrum disorder and poorer developmental outcomes. However, the numbers in the available studies were limited and further data were needed to reach firm conclusions.

Clinicians should continue to consult the wider findings of the review when considering prescribing of epilepsy medicines in female patients, particularly that lamotrigine (Lamictal) and levetiracetam (Keppra) were not associated with an increased risk of birth defects compared with the general population.

New national safety review of topiramate

The MHRA regularly reviews any emerging data relating to the safety of topiramate, as for all medicines.

A recently published study (Bjørk and colleagues1) reported prenatal exposure to topiramate to be associated with an increased risk of autism and intellectual disability. The Commission on Human Medicines considered the findings of this new study and advised that it provides robust evidence to support an association between prenatal exposure to topiramate and an increased risk of autism spectrum disorder, intellectual disability and the composite outcome of any neurodevelopmental disorder (see study for definition).

MHRA have now started a safety review to evaluate these findings in the context of the accumulating data relating to the benefits and risks of use of topiramate, with a particular focus on women of childbearing potential and during pregnancy. The review will also explore the need for additional risk minimisation measures to reduce

---

1Bjørk MH and others. Association of Parental Exposure to Antiseizure Medication with Risk of Autism and Intellectual Disability. JAMA Neurology: published 31 May 2022
the potential harms associated with the use of topiramate during pregnancy. More about the review is available on the MHRA website.

While the review is ongoing, we are alerting healthcare professionals to the findings of this new study and reminding you of the important risks and precautions to take when prescribing or dispensing topiramate in women of childbearing potential.

Further details on the findings of the new study

The study by Bjørk and colleagues is a large, well-conducted study using established data sources from 5 Nordic countries (Denmark, Finland, Iceland, Norway, and Sweden). It reports that children whose mothers use topiramate or valproate during pregnancy are at an increased risk of autism spectrum disorder, intellectual disability, and a composite outcome of any neurodevelopmental disorder. These risks are already known for valproate (see below).

Data from around 4.5 million mother-child pairs were examined and this included 24,825 children (0.6%) who were prenatally exposed to antiepileptic drugs. Of these, 16,170 were born to mothers who had epilepsy. These data were analysed to estimate the risk of autism spectrum disorder and intellectual disability after exposure to the 10 most frequently used antiepileptic drugs when used as monotherapy (one medicine) and the 5 most frequently used antiepileptic drugs when used as duotherapy (two medicines at the same time).

In unexposed children of mothers with epilepsy, the 8-year cumulative incidence of autism spectrum disorder and intellectual disability were 1.5% and 0.8% respectively compared with 4.3% and 3.1% in children of mothers with epilepsy exposed to topiramate. The adjusted hazard ratios for autism spectrum disorder and intellectual disability were 2.8 (95% CI 1.4 to 5.7) and 3.5 (95% CI 1.4 to 8.6).

A range of sensitivity analyses were conducted that broadly showed consistent and statistically significant effect estimates of a greater than 2-fold increase in risk of neurodevelopmental disorders across most of the analyses. The data also showed a dose-dependent effect for topiramate.

Topiramate and current pregnancy prevention requirements

Before the initiation of topiramate in a woman of childbearing potential, pregnancy testing should be performed, and the patient should be fully informed of the risks if used during pregnancy.

For epilepsy, alternative therapeutic options should be considered for women of childbearing potential. If topiramate is used, a highly effective contraception is strongly recommended, and the discussion with the patient should include information on both the risks associated with taking topiramate and of uncontrolled epilepsy during pregnancy.

For migraine prophylaxis, topiramate is contraindicated in pregnancy and in women of childbearing potential if not using a highly effective method of contraception. As
such, topiramate should not be prescribed for migraine prevention in a patient who is pregnant.

**Advice on contraceptive interactions**

Topiramate may reduce the effectiveness of steroidal contraceptives, including oral contraceptives. Alternative or concomitant methods of contraception should be considered. Consult clinical guidance, including that from the Faculty of Reproductive and Sexual Health Clinical Effectiveness Unit (May 2022).

When using any medicine with teratogenic potential, the most effective contraceptive method should be advised, taking into account their personal circumstances.

**Valproate: current strict restrictions**

Valproate (Epilim) is highly teratogenic and evidence supports a rate of congenital malformations of 10% in infants whose mothers took valproate during pregnancy and neurodevelopmental disabilities in approximately 30% to 40% of children. The available data show these risks are dose-dependent, however there is no safe dose of valproate that can be used in pregnancy.

Valproate should not be used in girls and women of childbearing potential unless other treatments are ineffective or not tolerated, as judged by an experienced specialist. Valproate is contraindicated in women of childbearing potential unless a pregnancy prevention programme is in place.

All healthcare professionals must continue to identify and review all female patients of childbearing potential on valproate, including when it is used outside the licensed indications. Specialists should discuss the risks and review their treatment according to their clinical condition and circumstances. Every effort should be made to switch to appropriate alternative treatment prior to conception and before contraception is discontinued.

The comprehensive safety review of antiepileptic drugs in pregnancy in 2021 showed that available information for lamotrigine (brand name Lamictal) and levetiracetam (brand name Keppra) does not suggest an increased risk of physical birth defects compared with the general population.

The MHRA continues to closely monitor the use of valproate in female patients in the UK and is considering the effectiveness of the current measures to support its safe use.

**Report suspected reactions on a Yellow Card**

Please continue to report any suspected adverse drug reactions (ADRs) associated with topiramate or any other medicines via the Yellow Card scheme.

All patients, caregivers, and healthcare professionals can report a Yellow Card when they suspect a medication used during pregnancy has caused an adverse reaction or adverse pregnancy outcome.
When reporting ADRs related to medicines used in pregnancy, information that is particularly valuable for assessment of the report includes:

- Timings of when the medicine was taken during the pregnancy
- The outcome of the pregnancy (when known)
- Details of any relevant family history, including any obstetric history
- For reports concerning congenital malformations, a detailed clinical description of any congenital anomaly and the results of any imaging (for example, scans), or laboratory tests
- Other relevant information, including other medications or substances taken during the pregnancy, as well as folic acid intake.

Report Yellow Cards using:

- The Yellow Card website
- The Yellow Card app; download from the Apple App Store or Google Play Store
- Some clinical IT systems for healthcare professionals (EMIS, SystmOne, Vision, MiDatabank, and Ulysses)

Yours sincerely

Prof Sir Michael McBride  Mrs Cathy Harrison
Chief Medical Officer  Chief Pharmaceutical Officer

Circulation List

Director of Public Health/Medical Director, Public Health Agency (for onward distribution to all relevant health protection staff)
Assistant Director Public Health (Health Protection), Public Health Agency
Director of Nursing, Public Health Agency
Assistant Director of Pharmacy and Medicines Management, SPPG (for onward distribution to Community Pharmacies)
Directors of Pharmacy HSC Trusts
Director of Social Care and Children, SPPG
Family Practitioner Service Leads, SPPG (for cascade to GP Out of Hours services)
Medical Directors, HSC Trusts (for onward distribution to all Consultants, Occupational Health Physicians and School Medical Leads)
Nursing Directors, HSC Trusts (for onward distribution to all Community Nurses, and Midwives)
Directors of Children’s Services, HSC Trusts
RQIA (for onward transmission to all independent providers including independent hospitals)
Joe Brogan, Assistant Director, Head of Pharmacy and Medicines Management, Strategic Planning and Performance Group (SPPG) (for onward distribution to SPPG Pharmacy and Medicines Management Team and community pharmacists)
Regional Medicines Information Service, Belfast HSC Trust
Regional Pharmaceutical Procurement Service, Northern HSC Trust
Professor Donna Fitzsimons, Head of School of Nursing and Midwifery QUB
Professor Sonja McIlfattrick, Head of School of Nursing, University of Ulster
Heather Finlay, CEC
Donna Gallagher, Open University
Professor Paul McCarron, Head of School of Pharmacy and Pharmaceutical Sciences, UU
Professor Colin McCoy, Head of School, School of Pharmacy, QUB
Professor Colin Adair, Postgraduate Pharmacy Dean, NI Centre for Pharmacy Learning and Development, QUB
Michael Donaldson, Head of Dental Services, SPPG (for distribution to all General Dental Practitioners)
Raymond Curran, Head of Ophthalmic Services, SPPG (for distribution to Community Optometrists)
Trade Union Side
Clinical Advisory Team
Louise McMahon, Director of Integrated Care, SPPG

This letter is available on the Department of Health website at